Drug Profile
Retigabine modified release
Alternative Names: Retigabine ER; Retigabine extended release; Retigabine MR; Retigabine sustained release; Retigabine XRLatest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Meda
- Developer Bausch Health Companies; GlaxoSmithKline
- Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
- Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Partial epilepsies
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies